Asthma is the most common and potentially deadly respiratory disease in the world that affects ~10% of the population.

Asthma patients live every day with shortness of breath, wheezing and cough. Asthma affects 20 million people in the US alone and accounts for ~400,000 deaths per year.

Asthma is on the rise, increasing by 19% in the US since 2001. Most people know someone with asthma but what might not be apparent is that can be very severe for a subset of patients with asthma. These patients experience wheezing, cough and shortness of breath every day seriously affects their ability to work, or go to school.

Asthma attacks, where these symptoms become so severe that additional medical care is needed like hospitalization or an emergency department visit, create a huge burden for our patients with severe asthma and a cost of close to $82 billion in health care expenditures and lost productivity.

Despite advances in the understanding of the immunology of asthma with improved medications and now biologics that target specific inflammatory pathways, we have not come close to eliminating asthma attacks.

Therefore, there is a critical need to develop better therapeutics to target the underlying inflammation while also controlling asthma symptoms across all types of asthma.​